93 related articles for article (PubMed ID: 2472494)
1. [Acute phase protein (alpha 1 AT) as a tumor marker in patients with ovarian cancer (OC)].
Kawai M; Iida N; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y
Gan No Rinsho; 1989 Jun; 35(7):799-803. PubMed ID: 2472494
[TBL] [Abstract][Full Text] [Related]
2. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
4. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
5. [Comparative studies on the value of acute phase proteins and CA-125 for monitoring patients with ovarian cancer].
Kölbl H; Tatra G; Schieder K; Bieglmayer C
Strahlenther Onkol; 1988 Dec; 164(12):724-8. PubMed ID: 2462754
[TBL] [Abstract][Full Text] [Related]
6. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
7. [Serum level of the tumor marker CA 125 in ovarian pathology].
Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
[TBL] [Abstract][Full Text] [Related]
8. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
9. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].
Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
11. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
13. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
Shi ZL
Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
[TBL] [Abstract][Full Text] [Related]
14. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
16. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
Yue K; Bian M; Zhu D; Liu W; Siu S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
[TBL] [Abstract][Full Text] [Related]
17. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
19. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]